Skip to main content

Table 5 Comparison between the randomized controlled trials of erenumab for the prevention of migraine and the present study

From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

 

ARISE [26]

NCT02066415 [17]

STRIVE [18]

LIBERTY [19]

American real-life data [21]

Italian real-life data [22]

Present study

General characteristics

 Migraine type

Episodic

Chronic

Episodic

Episodic

Chronic and episodic

83% chronic, 17% episodic

93.4% chronic, 6.6% episodic

 Dose (mg)

70

70

140

70

140

140

70 or 140

70

70 or 140

 No. of prior preventive treatment failures

< 2 (no response)

≤3 (no response)

≤2 (no response)

2–4

≤2

 Follow-up duration, months

3

3

6

3

2

2

6

 No. of treated patients

286

191

190

317

319

121

100

78 (13 episodic, 65 chronic)

89

Patient characteristics

 Female, %

85.7

87

84

84.5

85.3

80

83

75% (EM), 80% (CM)

87.6

 Mean age, years

42

41.4

42.9

41.1

40.4

44.6

 

47.1 (EM), 47.6 (CM)

46.8

 Mean migraine duration, years

22

20.7

21.9

29.1 (EM), 30.2 (CM)

28.2

 Medication overuse, %

41

41

61.5 (EM), 84.6 (CM)

71.9

 Prior preventive treatment failures, %

87.3

67

66

40.1

36.4

100

100

100

100

 Mean MMDs at baseline

8.1

17.9

17.8

8.3

8.3

9.2

10.9 (EM), 22.0 (CM)

19.8

Outcomes

 MMD decrease, mean days

−2.9

−6.6

−6.6

−3.2

−3.7

−1.8

−7 (EM), −15 (CM)

−12.4

 Triptan use days decrease, mean days

−1.2

−3.5

−4.1

−1.1

−1.6

−1.3

−5.6

 50% responders, %

39.3

40

41

43.3

50.0

30

100 (EM), 87.5 (CM)

74.1

 Adverse events %

48.1

44

47

57.3

55.5

55

34

1.3

22.5

 Serious adverse events %

1.1

3

1

2.5

1.9

2

5

2.2